Absolute Antibody Ltd., specialists in antibody sequencing, engineering and expression, today announced it has obtained CIR (Crédit d’Impôt Recherche) accreditation from the French Ministry of Higher Education, Research and Innovation. The French Research Tax Credit enables French companies to receive up to 30% tax relief on eligible R&D activities, and Absolute Antibody services and products are now approved for the program.
“We are pleased to receive CIR accreditation, as it allows our French customers to claim tax credits on projects with our company,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Absolute Antibody now has customers in more than 60 countries, as demand for recombinant antibody technology continues to increase worldwide, and this accreditation enables us to better serve both new and existing customers in France.”
Absolute Antibody offers custom antibody sequencing, engineering and expression services, as well as a unique catalog of engineered recombinant antibodies. Customers include leading pharmaceutical, biotechnology and diagnostic companies, as well as academic researchers worldwide, and Absolute Antibody has been committed to successfully serving this growing global customer base. In addition to obtaining CIR accreditation, other recent company milestones have included opening a North American office in Boston, Massachusetts, and significantly expanding its ISO-certified research and manufacturing facility in Northeast England.
About Absolute Antibody, Ltd.
Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats.
Antibody Engineering and Therapeutics Europe – Stand #26
11-13th June 2019